Printer Friendly

Confirmation of the recurrent ACVR1 617G>A mutation in South Africans with fibrodysplasia ossificans progressiva.

Fibrodysplasia ossificans progressiva (FOP) [OMIM 135100] is a rare genetic disorder in which ossification of connective tissue leads to severe disability. It is an autosomal dominant trait and affected persons have mutations in the activin A type 1 receptor gene (ACVR1), chromosomal locus 2q23-24. (1) ACVR1 is one of the f4 type 1 receptors that mediate in the highly conserved bone morphogenetic protein (BMP) signalling pathway, through a domain rich in glycine and serine (GS-domain) residues. (2,3)

Diagnosing FOP has depended on recognising characteristic clinical and radiological features, and until recently the causative mechanism remained elusive. (2,3) FOP molecular investigations has revealed that most affected individuals have the same single nucleotide change 617G>A in the ACVR1 gene. The base change is a missense mutation that leads to the substitution of arginine with histidine (R206H). The point mutation 617G>A in ACVR1 that occurs in the GS-domain alters the ligand-dependent sensitivity for BMP signalling in connective tissue progenitor cells. Under normal circumstances, type 1 receptors such as ACVR1 are inactive until stimulated by extracellular BMPs through phosphorylation. (1-3)

FOP diagnosis is often delayed owing to its rarity. The clinical manifestations may also be confused with those of arthrogryposis multiplex congenita, several genetic rigid-joint syndromes, and various forms of childhood rheumatic disease.

As most genetic analyses have been carried out in white and Asian populations, the question arises as to whether or not this specific mutation (617G>A) is associated with FOP in all populations. No sub-Saharan black molecular studies interrogating the genetics of ACVR1/ALK2 and its association with FOP have been reported. Therefore, we investigated whether the commonly reported ACVR1/ ALK2 617G>A recurrent mutation also causes FOP in indigenous South Africans.

Methods

Six persons with FOP (4 Xhosa, 1 coloured and 1 white) were available for molecular investigation (Table 1). Three of them were the subject of reports, including full clinical and radiological descriptions, concerning the management and dental implications of FOP in South Africa. (4,5)

The main features of FOP in the affected South Africans were consistent with the literature. The severity and rate of progression are variable. FOP often presents at birth with shortening and deviation of the great toes. General health remains good and early development is normal. In mid-childhood, tender subcutaneous lumps may appear, frequently on the upper region of the back, that become ossified, and widespread ectopic ossification develops in the connective tissues. The limbs, neck and jaw become tethered by bands of ossification resulting in immobility. Finally, movements are limited to the external muscle of the eye and the diaphragm. Death usually occurs by middle age from respiratory insufficiency.

Blood was obtained for molecular genetic analysis from the 6 FOP patients and 6 ethnic-matched controls after obtaining informed consent in accordance with the requirements of the Human Research Ethics Committee, University of Cape Town (ref HREC 026/2010--PB). Genomic DNA was extracted from peripheral blood leukocytes using a Qiagen DNA extraction kit (Valencia, USA). The single nucleotide polymorphism 617G>A in ACVR1 was analysed according to the method of Shore et al. (1) using PCR and restriction fragment length polymorphism (RFLP) using HphI and Cac8I. The 617G>A mutation in ACVR1 eliminates a Cac8I site and forms a new HphI site (Fig. 1). In addition, each of the samples was subjected to sequence analysis.

[FIGURE 1 OMITTED]

Results

The 350 bp PCR product from the normal allele (617G) after digestion with Cac8I showed the 3 bands (139, 114, and 97 bp) while the mutant allele (617A) appeared as 2 bands (253 and 97 bp) in persons with FOP. For HphI, PCR products of the 617G allele (normal) were not digested but PCR products of the 617A allele showed bands of 228 and 122 bp in the FOP patients. All 6 persons with FOP were heterozygous for the 617G>A mutation. The mutation was absent in all 6 controls. Sequence analysis (Fig. 2) revealed the heterozygous genotype in all affected individuals while the controls had the normal homozygous 617G/G genotype.

Discussion

Most individuals with FOP are sporadic, representing new mutations for the determinant gene. Although FOP has a worldwide distribution, there are few previous reports of affected persons in South Africa. (6) Four of the 6 persons investigated in Cape Town are Xhosa. Reports from several other parts of the world have confirmed the presence of the 617G>A specific mutation in persons with FOP. However, the concept of 1 specific mutation in ACVR1 is no longer tenable as evidenced by the reports associating 605G>T, 983G>A, 774G>C and 1067G>A with FOP in the absence of the recurrent 617G>A. (2,7) Nevertheless, the important feature of these mutations is that their resulting amino acid changes mostly occur in the GS or kinase coding domains. (7) This observation makes molecular sense in that different mutations in the ACVR1/ALK2 receptor gene could lead to different clinical manifestations of FOP. By extrapolation, mutations within the ACVR1/ALK2 receptor gene that cause variable ACVR1/ ALK2 receptor activity could also lead to different phenotypes, depending on the sensitivities of the domains in which they occur. (2,7)

[FIGURE 2 OMITTED]

This concept could also argue for the involvement of mutations in ACVR1 receptor gene in other related disorders such as some forms of myositis. (2,7)

The identification of the recurrent 617G>A mutation in almost all FOP patients worldwide, together with the narrowing of all reported mutations to the GS and kinase domains of the ACVR1/ ALK2 gene, provides a specific target of intervention in a critical signalling pathway. The prime target in FOP would be inhibition of the BMP signalling pathway, using RNA technology or monoclonal antibodies. (1,8) In South Africa, confirming the recurrent 617G>A mutation in all 6 patients suggests that genetic analysis can aid the diagnosis of suspected FOP, thereby negating the need for invasive procedures that can accelerate its progression.

Conclusions

Demonstrating that 6 affected South Africans with disparate antecedents have the same worldwide documented 617G>A mutation provides a firm starting point for establishing a diagnostic molecular testing facility for FOP in sub-Saharan Africa. In turn, awareness of FOP and the feasibility of molecular diagnostic confirmation would positively influence its medical management in Africa. The ubiquity of the 617G>A mutation could also facilitate research on identifying molecular intervention strategies that may be applied in FOP patients to slow the progression of the disorder, particularly by targeting the BMP signalling pathway.

Acknowledgements. Collet Dandara and Peter Beighton are grateful to the National Research Foundation (NRF) and the Medical Research Council (MRC) of South Africa for support. Collet Dandara thanks the Research Council of the University of Cape for research support.

Accepted 16 January 2012.

References

(1.) Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics 2006;38:525-527.

(2.) Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009a;30:379-390.

(3.) Kaplan FS, Pignolo RJ, Shore EM. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signalling. Cytokine & Growth Factor Reviews 2009b;20:399-407.

(4.) Scott C, Urban M, Arendse R, Dandara C, Beighton P. Fibrodysplasia ossificans progressiva in South Africa: difficulties in management in a developing country. J Clin Rheumatol 2011;17:38-41.

(5.) Roberts T, Stephen LXG, Scott C, Urban M, Sudi S, Beighton P. Fibrodysplasia ossificans progressive (FOP) in South Africa: dental implications in 5 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:11-18.

(6.) Connor JM, Beighton P. Fibrodysplasia ossificans progressiva in South Africa: case reports. S Afr Med J 1982;61:404-406.

(7.) Gregson CL, Hollingworth P, Williams M, et al. A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone 2011;48:654-658.

(8.) Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic ossification. Nature Medicine 2008;14:1363-1369.

Division of Human Genetics, Faculty of Health Sciences, University of Cape Town Medical School

Collet Dandara, PhD

Karen Fieggen, MB ChB, FCPaed, Cert Medical Genetics

Peter Beighton, OMB, MD, PhD, FRCP, FRSSA

Department of Paediatrics, Red Cross War Memorial Children's Hospital and University of Cape Town Medical School

Chris Scott, FCPaed (SA)

Division of Molecular Biology and Human Genetics, Faculty of Health Sciences, Stellenbosch University

Mike Urban, FCPSA, Cert Medical Genetics

Division of Rheumatology, University of Cape Town and Groote Schuur Hospital

Regan Arendse, PhD, FCPSA

Corresponding author: C Dandara (collet.dandara@uct.ac.za)
Table 1. Main features of the 6 subjects with FOP

                    Year of
Patient    Gender   birth      Ancestry

FOP 1.1    F        2005       Xhosa

FOP 2.1    M        1965       Xhosa

FOP 3.1    F        1964       Xhosa

FOP 4.1    F        2003       Coloured

FOP 5.1    F        2009       Xhosa

FOP 6.1    F        1997       White

Patient    Disability                     Additional comments

FOP 1.1    Extensive heterotopic          Legs spared at this point.
           ossification over back and
           spine. Arms and neck
           immobile and arms tethered
           to thorax.

FOP 2.1    Spine and arms completely      No clinical features of
           immobile. Able to walk         thoracic insufficiency
           unaided.                       syndrome. Gainfully
                                          employed.

FOP 3.1    Completely immobile. Only      Profound iron deficiency
           able to move eyes and          anaemia owing to diet of tea
           tongue.                        and bread as unable to open
                                          mouth and chew. Thoracic
                                          insufficiency syndrome and
                                          pulmonary hypertension.

FOP 4.1    Heterotopic ossification       Presented after injury at
           over back and spine. Arms      school. Has had serious fall
           and neck immobile and arms     owing to inability to
           tethered to thorax.            protect with arms and
                                          developed large swelling
                                          over right eye.

FOP 5.1    Hard mass between scapulae.    Fitted with a helmet to
           Rigid cervical spine and       protect against head
           limited abduction of arms.     injuries.

FOP 6.1    Spinal immobility noted only   Had surgical correction of
           months before diagnosis.       toes at 5 months of age.
COPYRIGHT 2012 South African Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research
Author:Dandara, Collet; Scott, Chris; Urban, Mike; Fieggen, Karen; Arendse, Regan; Beighton, Peter
Publication:South African Medical Journal
Article Type:Report
Geographic Code:6SOUT
Date:Jul 1, 2012
Words:1681
Previous Article:The South African Paediatric Tumour Registry--25 years of activity.
Next Article:GST polymorphisms and early-onset coronary artery disease in young South African Indians.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters